Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 6, 1999, Pages 1033-1039

  Ghiso, Neil ^a   Rohan, Richard M ^a   Amano, Shiro ^a,b   Garland, Rebecca ^a   Adamis, Anthony P ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ANILINO 5,8 QUINOLINEQUINONE; CYCLIC GMP; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHORBOL ESTER; VASCULOTROPIN;

ARTICLE; DOSE RESPONSE; ENZYME ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOASSAY; MUTANT; NORTHERN BLOTTING; ONCOGENE RAS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION;

3T3 CELLS; ANIMALS; ANOXIA; CELL LINE; CYCLIC CMP; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENES, RAS; HUMANS; LYMPHOKINES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; RETINA; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032903943     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
2. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
3. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
4. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
5. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
6. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
7. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF- receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
8. Garrido C, Saule S, Gospodarowicz D. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors. 1993;8:109-117.
9. Harada S, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest. 1994;93:2490-2496.
10. Cullinan-Bove K, Koos RD. Vascular endothelial growth factor/ vascular permeability factor expression in the fat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 1993;133:829-837.
11. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:1667-1675.
12. Pournaras CJ, Miller JW, Gragoudas ES, et al. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol. 1997;115:1553-1558.
13. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
14. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem. 1994;269:4355-4359.
15. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995; 375:577-581.
16. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 1997;386: 403-407.
17. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 1995;370:203-208.
18. Liu Y, Cox SR, Monta T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5′ enhancer. Circ Res. 1995;77:638-643.
19. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest. 1995;95:1798-1807.
20. Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med. 1997;3:879-886.
21. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Anriopoulou P, Peristeris P, Maragoudakis ME. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol. 1994;111: 894-902.
22. Palmer RN, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
23. Schmidt HW, Walter U. NO at work. Cell. 1994;78:919-925.
24. Garbers DL. Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell. 1992;74:1-4.
25. Peng HB, Libby P, Liao JK. Induction and stabilization of IkB alpha by nitric oxide mediates inhibition by NFkB. J Biol Chem. 1995; 270:14214-14219.
26. Matthews JR, Botting CH, Panico M, Morris HR, Hay RT. Inhibition of NFkB DNA binding by nitric oxide. Nucleic Acids Res. 1997;24: 2236-2242.
27. Ohigashi T, Brookins J, Fisher JW. Interaction of nitric oxide and cyclic guanosine 3′,5′-monophosphate in erythropoietin production. J Clin Invest. 1993;92:1587-1591.
28. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasocontrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest. 1993;92:99-104.
29. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
30. Lu M, Kuroki M, Amano S, et al. Advanced glycation endproducts increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
31. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
32. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA. 1997;94:861-866.
33. Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-alpha-induced cell death. Science. 1996;274:782-784.
34. Chomczynski P, Sacchi N. Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
35. Gilman M, Ausubel FM, Brent R, et al., eds. Ribonuclease protection assay. Current Protocols in Molecular Biology. New York: John Wiley and Sons; 1989.
36. Hod Y. A simplified ribonuclease protection assay. Biotechniques. 1992;13:852-853.
37. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575-4580.
38. Moncada SR, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
39. Baeurle PA, Baltimore D. NF-kB. Ten years after. Cell. 1996;87:13-20.
40. De Caterina R, Libby P, Pen H-B, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
41. Donati G, Pournaras CJ, Pizzolato GP, Tsacopoulos M. Decreased nitric oxide production accounts for secondary arteriolar constriction after retinal branch vein occlusion. Invest Ophthalmol Vis Sci. 1997;38:1450-1457.
42. Maynard KI, Chen D, Arango PM, Ogilvy CS. Nitric oxide produced during ischemia improves functional recovery in the rabbit retina. Neuroreport. 1996;8:81-85.
43. Jacquemin E, de KY, Thillaye B, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin- induced uveitis rats. Invest Ophthalmol Vis Sci. 1996;37:1187-1196.
44. van der Zee R, Murohara T, Luo Z, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997;95:1030-1037.
45. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.